CY1124328T1 - Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστων - Google Patents
Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστωνInfo
- Publication number
- CY1124328T1 CY1124328T1 CY20211100154T CY211100154T CY1124328T1 CY 1124328 T1 CY1124328 T1 CY 1124328T1 CY 20211100154 T CY20211100154 T CY 20211100154T CY 211100154 T CY211100154 T CY 211100154T CY 1124328 T1 CY1124328 T1 CY 1124328T1
- Authority
- CY
- Cyprus
- Prior art keywords
- active
- bone formation
- effective control
- optimal bone
- phosphorus serum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001132—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009474P | 2014-06-09 | 2014-06-09 | |
| PCT/US2015/033226 WO2015191312A1 (en) | 2014-06-09 | 2015-05-29 | The effective and efficient control of serum phosphate for optimal bone formation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124328T1 true CY1124328T1 (el) | 2022-07-22 |
Family
ID=54769049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100154T CY1124328T1 (el) | 2014-06-09 | 2021-02-23 | Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστων |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US10639360B2 (https=) |
| EP (3) | EP3845245B1 (https=) |
| JP (2) | JP6808493B2 (https=) |
| KR (4) | KR102947335B1 (https=) |
| CN (1) | CN106604743A (https=) |
| AR (2) | AR100689A1 (https=) |
| AU (1) | AU2015275128C1 (https=) |
| BR (2) | BR112016028567A2 (https=) |
| CA (1) | CA2949234C (https=) |
| CL (1) | CL2016003179A1 (https=) |
| CY (1) | CY1124328T1 (https=) |
| DK (2) | DK3151859T3 (https=) |
| ES (2) | ES3040805T3 (https=) |
| FI (1) | FI3845245T3 (https=) |
| HR (2) | HRP20210250T1 (https=) |
| HU (2) | HUE053271T2 (https=) |
| LT (2) | LT3845245T (https=) |
| MX (2) | MX381052B (https=) |
| PE (1) | PE20170248A1 (https=) |
| PL (2) | PL3845245T3 (https=) |
| PT (2) | PT3845245T (https=) |
| RS (2) | RS61443B1 (https=) |
| SI (2) | SI3151859T1 (https=) |
| SM (2) | SMT202500342T1 (https=) |
| WO (1) | WO2015191312A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2559228C (en) | 2004-04-21 | 2016-06-21 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| MX381052B (es) | 2014-06-09 | 2025-03-12 | Ultragenyx Pharmaceutical Inc | El control efectivo y eficaz del fosfato serico para una osificacion optima. |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| MX389350B (es) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones. |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| CN108350440A (zh) | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| CN106709662B (zh) * | 2016-12-30 | 2021-07-02 | 山东鲁能软件技术有限公司 | 一种电力设备运行工况划分方法 |
| EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| BR112021019337A2 (pt) * | 2019-03-29 | 2021-12-07 | Atarga Llc | Anticorpo anti-fgf23 |
| CA3161266A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| AU2021337652B2 (en) | 2020-09-04 | 2025-01-30 | Alexion Pharmaceuticals, Inc. | Methods for treating bone mineralization disorders |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| EP4676955A2 (en) * | 2023-03-10 | 2026-01-14 | Ultragenyx Pharmaceutical Inc. | Human fgf23-binding antibodies with improved affinity and efficacy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| AU2005202100A1 (en) | 1999-05-11 | 2005-06-09 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| ATE461213T1 (de) | 2000-07-19 | 2010-04-15 | Advanced Res & Tech Inst | Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung |
| EP2233571B1 (en) | 2000-08-11 | 2012-11-07 | Kyowa Hakko Kirin Co., Ltd. | Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| JP4527982B2 (ja) * | 2001-12-28 | 2010-08-18 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子−２３に対する抗体 |
| EP1833848A2 (en) * | 2004-12-09 | 2007-09-19 | Lajolla Institute for Allergy and Immunology | Novel tnf receptor regulatory domain |
| US8158725B2 (en) | 2005-08-22 | 2012-04-17 | Bridgestone Corporation | Functionalized polymers and tires therefrom |
| US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
| US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
| WO2012050673A1 (en) | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
| US9982023B2 (en) * | 2011-11-15 | 2018-05-29 | Sanford-Burnham Medical Research Institute | Compositions and methods for treating autoimmune and inflammatory disorders |
| MX381052B (es) | 2014-06-09 | 2025-03-12 | Ultragenyx Pharmaceutical Inc | El control efectivo y eficaz del fosfato serico para una osificacion optima. |
-
2015
- 2015-05-29 MX MX2016016296A patent/MX381052B/es unknown
- 2015-05-29 CA CA2949234A patent/CA2949234C/en active Active
- 2015-05-29 SI SI201531522T patent/SI3151859T1/sl unknown
- 2015-05-29 BR BR112016028567A patent/BR112016028567A2/pt not_active Application Discontinuation
- 2015-05-29 KR KR1020247017683A patent/KR102947335B1/ko active Active
- 2015-05-29 WO PCT/US2015/033226 patent/WO2015191312A1/en not_active Ceased
- 2015-05-29 LT LTEP20208220.2T patent/LT3845245T/lt unknown
- 2015-05-29 ES ES20208220T patent/ES3040805T3/es active Active
- 2015-05-29 DK DK15806501.1T patent/DK3151859T3/da active
- 2015-05-29 PT PT202082202T patent/PT3845245T/pt unknown
- 2015-05-29 KR KR1020177000293A patent/KR20170013993A/ko not_active Ceased
- 2015-05-29 US US14/725,320 patent/US10639360B2/en active Active
- 2015-05-29 RS RS20210173A patent/RS61443B1/sr unknown
- 2015-05-29 LT LTEP15806501.1T patent/LT3151859T/lt unknown
- 2015-05-29 HR HRP20210250TT patent/HRP20210250T1/hr unknown
- 2015-05-29 KR KR1020217024284A patent/KR20210099180A/ko not_active Ceased
- 2015-05-29 HR HRP20251099TT patent/HRP20251099T1/hr unknown
- 2015-05-29 PE PE2016002698A patent/PE20170248A1/es unknown
- 2015-05-29 SM SM20250342T patent/SMT202500342T1/it unknown
- 2015-05-29 EP EP20208220.2A patent/EP3845245B1/en active Active
- 2015-05-29 EP EP25184948.5A patent/EP4647444A3/en active Pending
- 2015-05-29 FI FIEP20208220.2T patent/FI3845245T3/fi active
- 2015-05-29 ES ES15806501T patent/ES2851674T3/es active Active
- 2015-05-29 AR ARP150101715A patent/AR100689A1/es unknown
- 2015-05-29 BR BR122023023102-3A patent/BR122023023102A2/pt not_active Application Discontinuation
- 2015-05-29 PT PT158065011T patent/PT3151859T/pt unknown
- 2015-05-29 KR KR1020267009825A patent/KR20260051107A/ko active Pending
- 2015-05-29 AU AU2015275128A patent/AU2015275128C1/en active Active
- 2015-05-29 PL PL20208220.2T patent/PL3845245T3/pl unknown
- 2015-05-29 SM SM20210096T patent/SMT202100096T1/it unknown
- 2015-05-29 HU HUE15806501A patent/HUE053271T2/hu unknown
- 2015-05-29 JP JP2016569651A patent/JP6808493B2/ja active Active
- 2015-05-29 CN CN201580039280.XA patent/CN106604743A/zh active Pending
- 2015-05-29 SI SI201532076T patent/SI3845245T1/sl unknown
- 2015-05-29 HU HUE20208220A patent/HUE073105T2/hu unknown
- 2015-05-29 PL PL15806501T patent/PL3151859T3/pl unknown
- 2015-05-29 DK DK20208220.2T patent/DK3845245T3/da active
- 2015-05-29 RS RS20250889A patent/RS67294B1/sr unknown
- 2015-05-29 EP EP15806501.1A patent/EP3151859B1/en active Active
-
2016
- 2016-12-08 MX MX2021003740A patent/MX2021003740A/es unknown
- 2016-12-09 CL CL2016003179A patent/CL2016003179A1/es unknown
-
2020
- 2020-03-26 US US16/831,179 patent/US11202822B2/en active Active
- 2020-12-09 JP JP2020204298A patent/JP6993490B2/ja active Active
-
2021
- 2021-02-23 CY CY20211100154T patent/CY1124328T1/el unknown
- 2021-11-12 US US17/525,738 patent/US11771748B2/en active Active
-
2023
- 2023-08-07 US US18/366,447 patent/US12358976B2/en active Active
- 2023-11-14 AR ARP230103059A patent/AR131056A2/es unknown
-
2025
- 2025-06-11 US US19/235,347 patent/US20260035449A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124328T1 (el) | Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστων | |
| CY1125327T1 (el) | Anti-pd-1 αντισωματα και συνθεσεις | |
| EA201791018A1 (ru) | Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы | |
| EA201591599A1 (ru) | Ингибиторы ido | |
| EA201690306A1 (ru) | Ингибиторы ido | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| BR112017021021A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
| EA201690152A1 (ru) | Ингибиторы ido | |
| EA201890630A1 (ru) | Антитела против pd-1 и способы их применения | |
| EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
| CO2017000386A2 (es) | Compuestos de heteroarilo para la inhibición de cinasa | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201891251A1 (ru) | Бициклические ингибиторы pad4 | |
| BR112015032595A8 (pt) | inibidores de ido | |
| JO3357B1 (ar) | مركبات إيميدازوبيروليدينون | |
| BR122020024446B8 (pt) | Compostos para modulação da expressão do receptor do hormônio de crescimento | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| BR112016017041A2 (pt) | Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição | |
| BR112016027881A2 (pt) | antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv | |
| BR112015023203A8 (pt) | métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer. | |
| BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
| EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. |